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Background: While novel drugs have been developed, docetaxel remains one of the standard initial systemic
therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of
docetaxel, its severe adverse effects sometimes distress patients. Therefore, it would be very helpful to predict the
efficacy of docetaxel before treatment. The aims of this study were to evaluate the potential value of patient
characteristics in predicting overall survival (OS) and to develop a risk classification for CRPC patients treated with
docetaxel-based chemotherapy.
Methods: This study included 79 patients with CRPC treated with docetaxel. The variables, including patient
characteristics at diagnosis and at the start of chemotherapy, were retrospectively collected. Prognostic factors
predicting OS were analyzed using the Cox proportional hazard model. Risk stratification for overall survival was
determined based on the results of multivariate analysis.
Results: PSA response ≥50 % was observed in 55 (69.6 %) of all patients, and the median OS was 22.5 months. The
multivariate analysis showed that age, serum PSA level at the start of chemotherapy, and Hb were independent
prognostic factors for OS. In addition, ECOG performance status (PS) and the CRP-to-albumin ratio were not
significant but were considered possible predictors for OS. Risk stratification according to the number of these risk
factors could effectively stratify CRPC patients treated with docetaxel in terms of OS.
Conclusions: Age, serum PSA level at the start of chemotherapy, and Hb were identified as independent
prognostic factors of OS. ECOG PS and the CRP-to-albumin ratio were not significant, but were considered possible
predictors for OS in Japanese CRPC patients treated with docetaxel. Risk stratification based on these factors could
be helpful for estimating overall survival.
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Prostate cancer is currently the most common malignancy
in men from Western countries, and its occurrence has
recently been increasing in Japan.
Because most prostate cancers grow in an androgen-
dependent manner, androgen-deprivation therapy has
been the initial treatment for recurrent or metastatic* Correspondence: keito608@wakayama-med.ac.jp
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gen deprivation, prostate cancer finally becomes refractory
to hormonal manipulation and is then defined as
castration-resistant prostate cancer (CRPC) [3, 4].
Recently, possible therapeutic strategies for CRPC have
been increasing [5–8]. Novel therapies including enzalu-
tamide, abiraterone acetate, cabazitaxel, sipuleucel-T,
and radium 223 have been approved for therapy of
CRPC patients. Enzalutamide and abiraterone acetate
have shown their efficacy in not only the post-docetaxelicle is distributed under the terms of the Creative Commons Attribution 4.0
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patients with no visceral metastasis, enzalutamide and
abiraterone are recommended as well as docetaxel in the
NCCN guideline. Moreover, in patients with visceral me-
tastasis, these novel agents have been approved by FDA
in the pre-chemotherapy setting. However, it was in
2014 that these agents were approved in Japan. In
addition, the efficacy of novel therapies is still limited,
and the prognoses of CRPC patients still remain poor.
To date, docetaxel, a natural taxane from Taxus
baccata, has been established as effective and has been
widely used in CRPC treatment [11, 12]. While novel
drugs have been developed, docetaxel remains one of
the standard initial systemic therapies for CRPC patients.
In the EAU guideline 2014, docetaxel is still recom-
mended as the first-line chemotherapeutic agent, espe-
cially in patients with evidence of progressive disease.
Docetaxel is also recommended as the first-line drug in
the NCCN guideline 2015. Despite of the excellent anti-
tumor effect of docetaxel, its severe adverse effects, in-
cluding myelosuppression, sometimes distress patients.
Therefore, it would be helpful to predict the efficacy of
docetaxel before treatment. Since novel agents such as
enzalutamide and abiraterone acetate are now available,
appropriate selection of CRPC patients using prognostic
factors is crucial when choosing first-line therapy.
A predictive factor is a measurement that is associated
with response or lack of response to a particular therapy.
In contrast, a prognostic factor is a measurement that is
associated with patient’s prognoses with or without
treatment. Several prognostic factors in CRPC patients
have been reported, and some nomograms or risk classi-
fications have been developed. However, the magnitude
of the benefit provided by each factor has varied among
studies.
We previously reported that visceral metastases, in-
cluding lung, liver and lymph nodes and excluding bone,
and pretreatment anemia (hemoglobin < 11.3 g/dL) were
two independent factors predicting overall survival in
patients who received docetaxel chemotherapy for pros-
tate cancer [13]. In a previous study, we collected the
data from not only our hospital but also our related
hospitals. Thus, the cohort in that study was rather
heterogeneous regarding the indications, chemother-
apy regimens, and amount of missing data. In the
present study, patients only from our institute were
targeted, and more variables, such as the neutrophil-
to-lymphocyte ratio (NLR) and the C-reactive protein
(CRP)-to-albumin ratio, were evaluated as predictors
of overall survival.
The aims of this study were to evaluate the potential
value of patient characteristics in predicting overall sur-
vival (OS) and to develop a risk classification for CRPC
patients treated with docetaxel-based chemotherapy.Methods
Patients and treatment
Patients with CRPC treated with docetaxel chemotherapy
at the Wakayama Medical University Hospital (Wakayama,
Japan) from June 2005 to May 2014 were included in this
study. The eligibility criteria included histopathologically
diagnosed adenocarcinoma of the prostate and confirmed
failure of prior androgen deprivation therapy. If PSA
increased after confirmation of the existence of anti-
androgen withdrawal syndrome and alternative antiandro-
gen therapy, we judged that prior androgen deprivation
therapy was a failure. No patient was administered abira-
terone or enzalutamide or sipuleucel-T. In general,
patients received 70 mg/m2 of docetaxel intravenously
every 3 or 4 weeks. The recommended dose of docetaxel
in the NCCN guidelines is 75 mg/m2, however the 70 mg/
m2 dose is commonly used in Japan. This is because se-
vere myelosuppression is more likely to develop in Japa-
nese than Europeans and Americans. If necessary, dose
reduction and interval extension were allowed, based on
the patient’s overall condition. Prednisone 5 mg was
routinely administered twice daily simultaneously with
hormonal therapy for medical or surgical castration.
Treatment with docetaxel was continued until disease
progression, unacceptable adverse events, or the patient’s
refusal. Disease progression was defined as increases in
the number of evaluable lesions observed or in size of
existing lesions by RECIST 1.1 on imaging tests and/or
biological progression characterized by an elevated serum
PSA level of 25 % and an absolute increase of ≥2 ng/mL
than the nadir. As a general rule, PSA increase required at
least two times.
This study was approved by the institutional review
board of Wakayama Medical University (approval num-
ber 1672). Written informed consent to participate in
this study was not obtained from patients since this
study was a retrospective observational study for ordin-
ary medical practice. Instead, information about this
clinical study was disclosed at the web page of our
hospital and posted at visitor consultation rooms in our
hospital. If patients refused the use of their clinical data,
we should have excluded their data from our study.
However, no patient refused to provide his data for our
study.
Assessment
The variables, including patients’ characteristics at diagno-
sis (serum PSA level, Gleason score, and metastatic sites)
and characteristics at the start of chemotherapy (age,
ECOG performance status (PS), significant clinical pain,
precedent treatment, serum PSA level, duration from
initiation of androgen deprivation therapy, complete blood
count, biochemical profile, combined drugs) were
collected retrospectively. The NLR was calculated from
Table 1 Patient characteristics
n = 79
Median age (range), years 72 (52–86)
ECOG performance status, n (%)
0 52 (65.8)
1 15 (19.0)
> = 2 12 (15.2)
Significant pain, n (%) 32 (40.5)
Median PSA at prostate cancer dianosis
(range), ng/mL
125.2 (6.8–18778.0)
Gleason score, n (%)
> =8 43 (54.4)
< =7 36 (45.6)
Metastatic site, n (%)
bone 41 (51.9)
Lymph nodes 35 (44.3)
Lung 2 (2.5)
Liver 2 (2.5)
Prior treatment, n (%)
Prostatectomy 9 (11.4)
Radiotherapy 17 (21.5)
Combined androgen blockade 79 (100)
Combination treatment, n (%)
Bisphosphonate 23 (29.1)
Estramustine 54 (68.4)
Median PSA at docetaxel initiation (range), ng/mL 43.2 (2.7–3133.7)
Median androgen deprivation therapy
administration period (range), months
31.4 (2.8–152.6)
Median serum markers at the start of docetaxel
therapy (range)
Hemoglobin, g/dL 11.9 (6.6–14.9)
NLR 2.9 (0.8–18.6)
Cre, mg/dL 0.8 (0.5–2.1)
ALP, IU/L 277 (1.9–4151.0)
LDH, IU/L 231 (123–594)
CRP-to-Albumin Ratio 7.3 (0.5–225.3)
Abbreviations: ECOG eastern cooperative oncology group, PSA prostate-specific
antigen, NLR neutrophil-to-lymphocyte ratio, Cre creatinine, ALP alkaline
phosphatase, LDH lactate dehydrogenase
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CRP-to-albumin ratio was calculated from the CRP value
and the albumin value using the formula: CRP value/albu-
min value) × 100.
The goal of the of the study was to determine the
effect of patient characteristics on OS, calculated as the
interval between the first day of docetaxel administration
and the date of death or the last follow-up visit for
censored (living) patients.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware. OS was determined according to the Kaplan-Meier
method. Univariate and multivariate analyses of OS were
performed to compare the prognostic factors in a Cox
proportional hazards analysis. Continuous data were
divided into 2 groups according to their median values.
P < 0.05 was considered significant.
Results
During the study period, 79 CRPC patients received
docetaxel-based chemotherapy at our institution. The
patients’ characteristics at diagnosis and at the start of
chemotherapy are shown in Table 1. The median age
was 72 years (range: 52–86 years). ECOG PS was <1 in
52 (65.8 %) patients and ≥1 in 27 (34.2 %) patients. Most
patients had one or more metastases when they were di-
agnosed with prostate cancer. Overall, 9 (11.4 %) and 17
(21.5 %) patients underwent radical prostatectomy and
radiation therapy, respectively. The median androgen
deprivation therapy administration period was 31.4
months (range: 2.8–152.6 months). The median serum
PSA level at chemotherapy initiation was 43.2 ng/mL
(range: 2.7–3133.7 ng/mL). 54 patients (68.4 %) simul-
taneously received estramustine. Oral estramustine (560
mg) was administered on days 1 to 5 and days 8 to 12.
However, adverse events associated with estramustine,
such as thromboembolic events, did not develop.
The median number of chemotherapy cycles was 6
(range: 1–43). 20 patients (25.3 %) required dose reduc-
tion due to treatment intolerance or side effects. A total
of 71 patients (89.9 %) discontinued docetaxel treatment
because of disease progression (N = 39, 54.9 %), adverse
events (N = 24, 33.8 %), patient’s refusal (N = 3, 4.2 %),
and other reasons (N = 5, 7.0 %), respectively. The
remaining 8 patients (10.1 %) were still undergoing do-
cetaxel treatment during the course of the study. The
median number of chemotherapy cycles in patients who
discontinued treatment because of adverse events was
2.5 (range: 1–14).
Waterfall plots of the PSA response are shown in
Fig. 1. PSA responses ≥0 %, ≥30 %, and ≥50 % were
observed in 69 (87.3 %), 64 (81.0 %), and 55 (69.6 %) of
the total patients, respectively.During the observation period (median 15.1 months,
range: 1.8–53.4 months), 36 of all 79 patients (53.2 %)
died of prostate cancer, and 6 (7.6 %) died of another
cause. The median OS was 22.5 months, and the 1-year
OS rate was 78.8 %.
Univariate and multivariate Cox proportional hazards
regression models were used to investigate pre-treatment
predictors of OS (Table 2). Among several predictors,
age ≥ 72 years, ECOG PS ≥ 1, serum PSA level at the start
of chemotherapy ≥ 40 ng/mL, duration from initiation of
Fig. 1 Waterfall plot of PSA response. PSA responses of ≥0 %, ≥30
%, and ≥50 % are seen in 69 (87.3 %), 64 (81.0 %), and 55 (69.6 %)
patients, respectively
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g/dL, ALP ≥ 300 IU/L, and LDH ≥ 230 IU/L were
identified as significant predictors for OS on univariate
analysis. Furthermore, significant clinical pain, NLR ≥ 3,
CRP-to-albumin ratio ≥ 7, and combination use ofTable 2 Univariate and multivariate analyses of associations betwee
Variable Univariate analysis
HR
Age > = 72 years 2.38
ECOG PS > =1 2.92
Significant pain 1.72
PSA at prostate cancer diagnosis > = 125 ng/mL 1.06










PSA at docetaxel initiation 3.45
Androgen deprivation therapy administration
period > = 30 months
0.46
Serum markers at the start of docetaxel therapy
Hemoglobin > = 12 g/dL 0.24
NLR > = 3 1.71
Cre > = 0.8 mg/dL 0.68
ALP > =300 IU/L 3.27
LDH > =230 IU/L 1.88
CRP-to-Albumin Ratio > =7 1.7
Abbreviations: ECOG Eastern Cooperative Oncology Group, PSA prostate-specific antige
LDH lactate dehydrogenaseestramustine were not significant, but were considered
possible predictors for OS. Of these factors, age ≥ 72 years
and serum PSA level at the start of chemotherapy ≥ 40 ng/
mL were independent unfavorable predictors of OS and
Hb ≥ 12.0 g/dL was an independent favorable predictor of
OS on multivariate analysis. ECOG PS ≥ 1 and CRP-to-
albumin ratio ≥ 7 were not significant, but they were
considered possible unfavorable predictors for OS.
To develop a risk classification model to help in the ap-
propriate selection of docetaxel chemotherapy in patients
with CRPC, five pre-treatment factors, including advanced
age (age ≥ 72 years), poor PS (ECOG PS ≥ 1), high serum
PSA level at the start of chemotherapy (PSA ≥ 40 ng/mL),
anemia (Hb < 12 g/dL), and high CRP-to-albumin ratio
(CRP-to albumin ratio ≥ 7) were used, and the cohort was
classified into three groups according to the presence
of these five risk factors. Patients with 0–1, 2–3, and
4–5 risk factors were classified as low (N = 21), inter-
mediate (N = 37), and high (N = 21) risk groups, re-
spectively. This model effectively stratified patients inn various pre-treatment parameters and overall survival
Multivariate analysis
95 % CI P value HR 95 % CI P value
1.23–4.60 0.01 4.07 1.68–9.90 <0.01
1.59–5.51 <0.01 2.18 1.00–4.77 0.05








0.99–6.47 0.05 1.35 0.49–3.68 0.56
1.76–6.77 <0.01 2.36 1.02–5.45 <0.05
0.25–0.85 0.01 0.76 0.37–1.54 0.44
0.12–0.48 <0.01 0.24 0.10–0.59 <0.01
0.93–3.15 0.09 1.33 0.62–2.85 0.46
0.37–1.26 0.22
1.70–6.30 <0.01 0.87 0.34–2.22 0.76
1.02–3.49 <0.05 1.24 0.62–2.46 0.55
0.92–3.12 0.09 2.34 0.91–6.05 0.08
n, NLR Neutrophil-to-Lymphocyte Ratio, Cre creatinine, ALP alkaline phosphatase,
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shown in Fig. 2.
Discussion
Two randomized trials demonstrated significant survival
improvements in CRPC patients treated with docetaxel-
based chemotherapy [11, 12], and it is widely used,
including in Japan. Recently, several novel agents, in-
cluding enzaltamide and abiraterone acetate, were
shown to prolong overall survival in CRPC patients and
have appeared on the market [5, 8]. However, docetaxel
still remains a standard option, especially in CRPC
patients with evidence of progressive disease. Accord-
ingly, this provides clinicians with a wide choice between
docetaxel and novel agents [14]. Therefore, it is crucial
to identify prognostic factors and develop a risk stratifi-
cation for CRPC patients treated with docetaxel.
Many prognostic models in patients with CRPC have
been developed using pre and post chemotherapeutic
factors. Although post chemotherapeutic factors, includ-
ing PSA decline, tumor response, and pain response, are
often used to evaluate patient’s prognosis [15, 16], it
might be more beneficial for CRPC patients to predict
the response and outcome before the initiation of
chemotherapy. Armstrong et al. reported that four
independent risk factors, including visceral metastases,
bone scan progression, significant pain, and anemia
(hemoglobin level < 13 g/dL), predicted OS well, and
they developed a risk stratification model for CRPC
patients treated with docetaxel [16]. This Armstrong risk
classification (ARC) is highly reliable because it was de-
veloped from 656 CRPC patients treated with docetaxel
and was also internally validated in 333 CRPC patients
who were administered mitoxantrone from among the
1006 CRPC patients in the TAX 327 study [11]. How-
ever, few reports have externally validated the ARC in
CRPC patients who were treated with docetaxel. Nakano
et al. reported that the ARC could predict the prognosis
in docetaxel-treated CRPC patients [17]. On the other
hand, Shiota et al. reported that the ARC failed to strat-
ify the cohort satisfactorily [18]. They showed that ALPFig. 2 Kaplan-Meier curves for overall survival (OS) according to risk groupvalue, visceral metastasis, and duration from initiation of
hormone treatment were independent prognostic factors
on multivariate analysis. Indeed, the reported prognostic
factors for CRPC patients have differed widely among
studies. The prognostic factors for CRPC patients re-
ported in previous studies are shown in Table 3. Other
than the above, Bamias et al. reported that baseline PSA
>100, pain, weight loss, and simultaneous extraosseous
and bone disease were associated with worse prognosis
in CRPC patients [19]. Matsuyama et al. reported that a
decrease of ≥ 50 % in the PSA, serum markers at the
start of docetaxel therapy (PSA, ALP, and CRP), and the
number of docetaxel courses were independent predic-
tors of OS, and ALP, hemoglobin, and age at the start of
docetaxel therapy were useful for deciding the duration
of docetaxel therapy in CRPC patients [20].
The pre-chemotherapeutic prognostic factors are
divided broadly into two categories. The first category
reflects cancer progression. PSA value, PSADT, bone scan
progression, and significant pain are included in this
category. The second category represents the patient’s
general condition. Age, ECOG PS, and CRP are included
in the second category. The magnitude of the benefit
provided by each factor has varied among studies.
In this retrospective study, prognostic factors were
identified using only prechemotherapeutic factors in a
single-institute Japanese cohort. The serum PSA level at
the start of chemotherapy and anemia have been
reported to be prognostic factors for CRPC patients in
previous studies [16, 21, 22], and these factors were
shown to be independent prognostic factors for CRPC
patients treated with docetaxel in the present study. In
addition, this study showed that age was also an inde-
pendent prognostic factor and suggested that ECOG PS
and the CRP-to-albumin ratio could be prognostic fac-
tors for CRPC patients. Accumulating evidence has indi-
cated that cancer and inflammation are linked [23], and
inflammation-based prognostic scores, including the
NLR, Glasgow Prognostic Score (GPS), and Prognostic
Nutritional Index (PNI), have been reported to have
prognostic value in patients with various types of cancerclassification
Table 3 The prognostic factors for CRPC patients reported in previous studies



























656 110 69 91 23 45–48 17.8–19.2 × × ○ × × ○ ○ ○
Nakano et al. 78 19.7 70 54 5 23 × × × × ○ ○※1 ○※1 ○※1 ×
Shiota et al. 97 81.3 70 83.5 15.5 44.3 20.8 × × × × × × × ○ ○ ○
Bamias et al. 94 84 71 87 54 16.2 × × × ○ ○ ×
Matsuyama
et al.
279 35.2 71 60.5 7.9 57.5 26 × × ○ ○ ○ ○ ×
Ito et al. 80 14.5 × × ○ ○ × × × ×
Nuhn et al. 238 91.2–112.9 68.3 90.3 16.5 14.4–18.3 × × ○ ○ × ×
Present study 79 43.2 72 51.9 5 69.6 22.5 ○ × ○ ○※2 ○ × × ×
Abbreviations: PSA prostate-specific antigen, DTX docetaxel, OS overall survival, PS performance status, Hb haemoglibin, CRP C-reactive protein, PSA DT prostate-sp ific antigen doubling time, ALP alkaline phosphatase,
ADT androgen deprivation therapy
○: Significant
×: Not significant
※1: The Armstrong risk classification was independent prognostic factor
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CRP and the NLR are useful clinical markers of the
systemic inflammatory response in predicting OS in
patients with CRPC treated with docetaxel [21, 22].
However, Kinoshita et al. reported that the CRP-to-
albumin ratio might be an independent prognostic
marker in patients with hepatocellular carcinoma and
may have comparable prognostic ability to other estab-
lished inflammation-based prognostic scores [29]. The
present study suggested that this novel inflammation-
based prognostic score could be a valuable prognostic
marker in CRPC patients.
Our risk stratification could effectively stratify CRPC
patients treated with docetaxel in terms of OS. Most of
the prognostic factors included in the ARC, such as
visceral metastases, bone scan progression, and signifi-
cant pain, reflect the metastases of cancer. On the other
hand, the prognostic factors included in the present risk
stratification reflect the patient’s general condition. This
difference was likely caused by the differences in the
baseline characteristics of target patients. In the TAX
327 study, the median serum PSA level at chemotherapy
initiation of the patients was over 100 ng/mL [11]. Bone
metastases were observed in more than 90 % of patients,
and visceral metastases were seen in about 20 %. How-
ever, in the present study, the median serum PSA level
at chemotherapy initiation was 43.2 ng/mL, and the
frequency of bone metastases or visceral metastases was
less. Therefore, in the present study, a PSA response of ≥
50 % from baseline was observed in about 70 % patients,
and this PSA response rate was better than in previous
clinical trials performed in Western countries, including
the TAX327 trial [11, 12]. Moreover, the median OS dur-
ation in this cohort was 22.5 months, while the median
OS duration in the TAX327 cohort was <20 months.
The difference of disease burden between our cohort
and the TAX327 cohort caused these differences of PSA
response and OS. Considering these facts, it appears that
factors representing disease progression might be associ-
ated with OS in patients with progressive disease, while
factors reflecting the patient’s general condition might
be correlated with OS in patients with less progressive
disease – namely, prostate cancer with low serum PSA
level at chemotherapy initiation or without bone metas-
tases and visceral metastases. Lower disease burden in
our cohort might be one of the reasons that significant
pain, included in ARC, was not a significant factor in
this study.
With the advent of novel agents, the demand for doce-
taxel in CRPC patients might slightly decrease. However,
the results of the CHAARTED trial indicate the new ef-
fect of docetaxel for prostate cancer, and the importance
of docetaxel will never be lost. Our study focused on the
prognostic factors in CRPC patients receiving docetaxel-based chemotherapy, but the study about the prognostic
factors in hormone sensitive prostate cancer (HSPC)
patients receiving docetaxel-based chemotherapy will be
needed.
This study had some limitations. First, the sample size
was small, and the observation period might not have
been long enough to determine the actual OS. Second,
this study was a retrospective study using data from a
single institution. Thirdly, many patients in our cohort
received estramustine. It is less likely to combine estra-
mustine to docetaxel based chemotherapy in Europe and
United States. In fact, EAU and NCCN guidelines do
not recommend to combine estramustine with docetaxel
based chemotherapy. However, serious adverse events of
estrogen, such as embolism, are reported to be rather
rare in Japanese patients [30]. Finally, most patients
required docetaxel dose reductions because of adverse
events. Additional larger confirmatory studies are
warranted to validate our results.
Conclusions
Age, serum PSA level at the start of chemotherapy, and
Hb were identified as independent prognostic factors of
OS, and ECOG PS and the CRP-to-albumin ratio were
not significant but were considered as possible predic-
tors for OS in Japanese CRPC patients treated with
docetaxel. Risk stratification based on these factors could
be helpful for estimating OS.
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